June 23, 2018 / 2:00 PM / 5 months ago

Novo's Tresiba shows improved blood sugar control, lower rates of hypoglycaemia than Toujeo

COPENHAGEN, June 23 (Reuters) - Diabetes drugmaker Novo Nordisk on Saturday presented its findings from the real-world evidence study CONFIRM, comparing the effectiveness of its own Tresiba drug with Sanofi’s Toujeo, at the American Diabetes Association’s 78th Scientific Sessions.

* Novo’s Tresiba demonstrated significantly improved blood sugar control and lower rates of hypoglycaemia versus Sanofi’s insulin glargine U300, marketed as Toujeo, in real-world evidence study.

* Adults with type 2 diabetes treated with Tresiba had a significant reduction in HbA1c and a 30 percent lower rate of hypoglycaemic episodes after starting basal insulin. (Reporting by Stine Jacobsen, editing by Teis Jensen)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below